AF-FLOW Registry to Evaluate Electrographic Flow Mapping in Patients Undergoing Ablation for Atrial Fibrillation

CompletedOBSERVATIONAL
Enrollment

25

Participants

Timeline

Start Date

September 12, 2022

Primary Completion Date

October 27, 2022

Study Completion Date

November 17, 2023

Conditions
Atrial Fibrillation, PersistentAtrial FibrillationArrhythmias, CardiacHeart Diseases
Interventions
DEVICE

Electrographic Flow™ (EGF) mapping and ablation

"Electrographic Flow™ (EGF) mapping enables the full spatiotemporal reconstruction of organized atrial electrical wavefront propagation to identify active sources or origins of excitation that may trigger atrial fibrillation (AF).~EGF mapping involves 1 minute recordings of unipolar electrograms from a basket catheter, which are then processed with the EGF algorithm (Ablamap® Software). Several basket catheter positions are acquired in standard positions in both the left and right atria. EGF-identified sources with activity levels exceeding the recommended threshold are deemed significant and are targeted for ablation. The success of the ablation is confirmed through an EGF remap, where elimination of the source is defined as reduction of EGF source activity below the threshold."

Trial Locations (5)

10029

Mount Sinai Hospital, New York

30309

Piedmont Atlanta Hospital, Atlanta

30606

Piedmont Healthcare, Athens

3015GD

Erasmus MC, Rotterdam

02-972

Medicover Hospital, Warsaw

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Cortex

INDUSTRY

lead

Ablacon, Inc.

INDUSTRY

NCT05481359 - AF-FLOW Registry to Evaluate Electrographic Flow Mapping in Patients Undergoing Ablation for Atrial Fibrillation | Biotech Hunter | Biotech Hunter